The invention relates to compositions for use in the treatment or prevention of pathogenic infections, rosacea, eczema and psoriasis in humans or animals. The compositions of the invention are also useful in the healing of wounds in a human or animal, and for killing or inactivating viruses on a surface.

The invention relates to compositions for use in the treatment or prevention of pathogenic infections, rosacea, eczema and psoriasis in humans or animals. The compositions of the invention are also useful in the healing of wounds in a human or animal, and for killing or inactivating viruses on a surface.

The present invention relates to a macromolecule-based nanostructure, such as a DNA-based nanostructure, for encapsulating a virus or viral particle, to a composition comprising a virus or viral particle encapsulated by such a macromolecule-based nanostructure according to the present invention, and to a method for encapsulating a virus or viral particle by using such a macromolecule-based nanostructure

The present invention relates to a macromolecule-based nanostructure, such as a DNA-based nanostructure, for encapsulating a virus or viral particle, to a composition comprising a virus or viral particle encapsulated by such a macromolecule-based nanostructure according to the present invention, and to a method for encapsulating a virus or viral particle by using such a macromolecule-based nanostructure

The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

##STR00001##

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

##STR00001##

Provided herein are compositions, methods, uses, and articles of manufacture for iodine treatment on mucosal membranes, and treatment of respiratory pathogens in this way—e.g., by inhalation and combined with the evaporation of steam. In certain embodiments, iodine treatment encompasses administration of compounds that release molecular iodine and/or physiologically active iodine-containing compounds.

The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I):

##STR00001##

(wherein
R.sup.6 and R.sup.7 may be the same or different and each represent a hydrogen atom or the like,
R.sup.8, R.sup.9, R.sup.10, and R.sup.11 may be the same or different and each represent a hydrogen atom or the like,
R.sup.1 represents lower alkyl which may be substituted with cycloalkyl, or the like, and
R.sup.3 represents optionally substituted aryl or an optionally substituted heterocyclic group).

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.